Q1 EARNINGS: Danaher's CEO change overshadows ho-hum Q1
This article was originally published in Clinica
Danaher’s long-time CEO Larry Culp has unexpectedly announced his retirement, overshadowing what Jefferies analyst Brandon Couillard described as a “modest Q1 beat.” Executive vice-president Thomas Joyce will take the reins in what the analyst expects will be a “smooth transition,” which should have “little impact to strategy.” Mr Culp has led Danaher for 13 years; he began his career at the firm in 1990.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.